Thrombotic Incidents in Patients with Myelofibrosis Suggest to be Independent of JAK2 V617F Mutational Status

Dragomira Nikolova1,2, Atanas Radinov3

1 Department of Medical Genetics, Medical University of Sofia, Sofia, Bulgaria
2 Laboratory of Genetics, St Ivan Rilski University Hospital, Sofia, Bulgaria
3 Clinic of Hematology, St Ivan Rilski University Hospital, Sofia, Bulgaria

Corresponding author: Dragomira Nikolova, Department of Medical Genetics, Medical University of Sofia, Sofia, Bulgaria; Email: gdnikolova@gmail.com; Tel.: +359 895 784 096

Received: 27 July 2021 • Accepted: 8 Oct 2021 • Published: 31 Aug 2022

Citation: Nikolova D, Radinov A. Thrombotic incidents in patients with myelofibrosis suggest to be independent of JAK2 V617F mutational status. Folia Med (Plovdiv) 2022;64(4):655-660. doi: 10.3897/folmed.64.e72175.

Abstract

Introduction: Myelofibrosis (MF) belongs to a group of conditions known as Philadelphia-negative myeloproliferative neoplasms (MPN). Bleeding or various vascular complications could be the main causes of morbidity and mortality in patients with MF. MPN-related thrombosis is a multifactorial process and in the case of myelofibrosis, little is known. The risk factors for thrombotic complications in MF have been rarely assessed.

Aim: The purpose of this study was to investigate the incidence of thrombotic events in MF and the role of JAK2 V617F mutation as a risk factor for thrombotic incidents in patients with MF.

Materials and methods: In our study of 37 patients, 35% had thrombotic events in the past. All patients were admitted to the Clinic of Hematology, St Ivan Rilski University Hospital, Sofia, Bulgaria between 2016 and 2019 and diagnosed based on the WHO criteria of 2016.

Results: The majority of patients (23, 62%) proved positive for JAK2 (Janus kinase) V617F mutation carrying one (16, 70%) or two (7, 30%) mutated alleles. Thirteen of the patients (35%) had a thrombotic event in the past and 9 of them (69%) were carriers of JAK2 V617F mutation. Fourteen patients of those without thrombotic history (24, 58%) were also carriers of JAK2 V617F mutation.

Conclusions: As a whole, we did not find a statistically significant difference between JAK2 V617F mutation and the frequency of thrombotic events. Rendering an account to the possible life-threatening complications, treatment decisions should be undertaken upon possible antithrombotic prevention in MF.

Keywords
JAK2 mutation, myelofibrosis (MF), thrombotic incidents, risk factor

INTRODUCTION

Myelofibrosis is a myeloproliferative neoplasm (MPN) characterized by proliferation of clonal hematopoietic stem cells and presence of extra fibrous tissue in the bone marrow of the patient.[1] JAK2 (V617F) is one of the three well-known driver mutations for the development of MF, together with point mutation in MPL and ins/deletion in CALR genes. It has been proven in several studies that JAK2 mutation prevails in patients with MF. According to
different sources, this percentage is between 50% and 60% of the patients.

Generally, the prognosis of MF is poor – between five and six years – and increases if treatment with Janus kinase (JAK) inhibitors is initiated or appropriate usage of bone marrow transplantation. Thrombotic events (venous and arterial thrombosis) in MPN could additionally decrease the lifetime of patients. That is why it is important to investigate whether patients with MF are prone to develop thrombotic episodes and what the factors increasing this risk are.

Venous or arterial thromboses are the main complications of BCR-ABL negative myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF).[3] JAK2 V617F mutational status has been commented as an independent prognostic factor for fatal and nonfatal cardiovascular complications in patients with myelofibrosis (MF).[4]

The link between the risk for the occurrence of thrombotic events in patients with MF and the carriership of JAK2 V617F mutation is still under investigation.

Our hypothesis was that JAK2 V617F mutation could be a risk factor for thrombotic events in patients with myelofibrosis. What is known at present is that the persistence of this mutation is usually low in ET (with incidence rates of 23%–57%), higher in PV (frequently over 50%, usually 65-97%), and 35-57% in idiopathic MF.[5]

**AIM**

The aim of this study was to investigate the incidence of thrombotic events in patients with MF and to clarify whether JAK2 V617F mutation could be considered as a single risk factor for thrombotic incidents in patients with MF.

**MATERIALS AND METHODS**

**Patients and ethical consent**

Thirty-seven patients were diagnosed with myelofibrosis (MF) between May, 2015 and December, 2019 at the Clinic of Hematology, St Ivan Rilski University Hospital, Sofia, Bulgaria based on the criteria of WHO 2016.[6] Written informed consent was obtained from the patients for their anonymized personal information to be published in this article.

**Detection of JAK2 V617F by RFLP analysis**

All patients were subjected to targeted DNA analysis for the detection of JAK2 V617F mutation by RFLP procedure which has been previously described.[2] The presence of fragments of three different sizes (241, 189 and 30 bp) on 2% agarose gel certifies the presence of the wild type allele, while the mutant allele remains undigested.

**History of thrombotic events and statistical analysis**

The history of thrombotic events after setting the diagnosis was recorded and summarized from the medical documents of the patients (thrombosis of the arteries/veins). The data were compared to the mutational status of the patients and the results were statistically analyzed by chi-square test. P-value less than 0.05 was accepted as a statistically significant difference between the analyzed groups.

**RESULTS**

Thirty-four of 37 patients were classified with primary MF (PMF), stage I (17 out of 34, 21%), stage II (17 out of 34, 50%), stage III (10 out of 34, 29%), respectively. Three patients had secondary MF developed after the initial diagnosis of essential thrombocythemia (post-ET).

The history of thrombotic events was recorded for all patients (Table 1). The thrombotic events observed in our patients included mainly portal vein thrombosis (PVT) and brain or splenic infarction. Interestingly, post-ET myelofibrotic patients did not show any thrombotic complications (Table 1). Around 35% (13 out of 37) of the myelofibrotic patients had confirmed positive thrombotic history. They were distributed approximately evenly by their sex – seven were males (53%) and six (47%) were females. Table 1 presents some clinical characteristics of the patients as age, sex, JAK2 mutational status, the presence of thrombotic incidents, and treatment of the specific patient, if any.

The mean values of the clinical parameters of thrombocytes (Thr), hemoglobin (Hg) and hematocrit (Hct) for patients with or without thrombotic events are shown in Table 2. The levels of thrombocytes, Hg and Hct are slightly higher in patients with thrombotic incidents compared to non-thrombotic patients. In our study, we did not find a statistical significance between the levels of Hg and Hct and the presence of JAK2 V617F mutation in homozygous or heterozygous state (p=0.173 and p=0.695, respectively); however, it was correlated with the level of Thr (p=0.098).

JAK2 V617F status was analyzed for all patients with MF: 23 patients (62%) were positive for the mutation having one or both alleles mutated (homozygous by the mutation, MM or heterozygous MN), while only 14 were JAK2 negative (34%) (Fig. 1). Among patients with thrombotic history (n=13), JAK2 V617F positive were nine (69%), the rest (4, 31%) were negative for the mutations. Among non-thrombotic patients (n=24), JAK2 V617F positive were 14 (58%), JAK2 V617F negative – 10 (42%) (Fig. 1).

**DISCUSSION**

The three major types of myeloproliferative neoplasms (myelofibrosis, essential thrombocythemia and polycythemia vera) have differences in terms of bleeding and throm-
Table 1. Characteristics of the patients with MF

| Year | Sex | Age | JAK2 status | Diagnosis and stage | Thr (×10^9/L) | Hg (g/L) | Hct (%) | Thrombotic event | Management                                                                 |
|------|-----|-----|-------------|---------------------|--------------|--------|--------|-----------------|---------------------------------------------------------------------------|
| 2017 | Male | 51  | NN          | PMF, stage I        | 293          | 45     | 0.144 (14.4) | -               | Blood transfusion                                                         |
| 2015 | Male | 65  | MN          | PMF, stage III      | 84           | 48     | 0.134 (13.4) | -               | Observation                                                               |
| 2017 | Male | 73  | MN          | MF, stage III, post-ET | 267         | 60     | 0.231 (23.1) | -               | Blood transfusion, targeted therapy by JAKAVI                             |
| 2017 | Male | 51  | NN          | PMF, stage I        | 830          | 69     | 0.233 (23.3) | Brain infarction           | Observation                                                               |
| 2018 | Male | 73  | MN          | PMF, stage II       | 36           | 69     | 0.217 (21.7) | -               | Blood transfusion                                                         |
| 2017 | Male | 94  | MN          | PMF, stage III      | 254          | 71     | 0.22 (22)   | -               | Hydrea                                                                   |
| 2019 | Male | 73  | MN          | PMF, stage III      | 533          | 72     | 0.21 (21)   | -               | Targeted therapy by JAKAVI                                               |
| 2017 | Female | 86 | NN         | PMF, stage II       | 97           | 76     | 0.215 (21.5) | -               | Hydrea, anticoagulant therapy                                             |
| 2019 | Female | 83 | NN         | Secondary MF, post-ET | 209         | 76     | 0.237 (23.7) | -               | Observation                                                               |
| 2016 | Female | 76 | MN         | PMF, stage III      | 42           | 80     | 0.24 (24)   | -               | Transfusion of erythrocyte concentration, targeted therapy by JAKAVI     |
| 2019 | Male | 66  | MN          | PMF, stage III      | 66           | 80     | 0.254 (25.4) | -               | Blood transfusion                                                         |
| 2018 | Male | 65  | MN          | PMF, stage III      | 37           | 85     | 0.289 (28.9) | Splenic infarction          | Observation                                                               |
| 2018 | Female | 79 | NN         | PMF, stage II       | 926          | 88     | 0.278 (27.8) | -               | Hydrea                                                                   |
| 2019 | Male | 69  | MM          | PMF, stage I        | 199          | 88     | 0.302 (30.2) | -               | Hydrea                                                                   |
| 2019 | Female | 55 | MN         | PMF, stage III      | 104          | 91     | 0.314 (31.4) | Splenic infarction          | Targeted therapy by JAKAVI                                               |
| 2016 | Male | 60  | NN          | PMF, stage II       | 135          | 94     | 0.281 (28.1) | -               | Observation                                                               |
| 2018 | Female | 80 | MN         | MF, stage II, post-ET | 550         | 98     | 0.303 (30.3) | -               | Observation                                                               |
| 2019 | Male | 72  | MN          | PMF, stage II       | 159          | 104    | 0.34 (34)   | -               | Observation                                                               |
| 2018 | Male | 63  | MN          | PMF, stage II       | 335          | 105    | 0.338 (33.8) | -               | Hydrea                                                                   |
| 2017 | Male | 46  | NN          | PMF, stage II       | 81           | 107    | 0.329 (32.9) | Portal vein thrombosis       | Hydrea                                                                   |
| 2016 | Female | 29 | MN         | PMF, stage II       | 304          | 109    | 0.316 (31.6) | Portal vein thrombosis       | Hydrea                                                                   |
| 2018 | Female | 47 | NN         | PMF, stage II       | 657          | 112    | 0.334 (33.4) | Portal vein thrombosis       | Hydrea, anticoagulant therapy                                             |
| 2015 | Female | 58 | NN         | PMF, stage I        | 177          | 115    | 0.32 (32)   | -               | Observation                                                               |
| 2018 | Female | 80 | MM         | PMF, stage II       | 699          | 121    | 0.409 (40.9) | Ischemic stroke of the brain    | Anticoagulant therapy                                                   |
| 2018 | Female | 57 | NN         | PMF, stage III      | 262          | 125    | 0.406 (40.6) | -               | Observation                                                               |
| 2017 | Female | 45 | MM         | PMF, stage II       | 281          | 126    | 0.395 (39.5) | Brain disease, unclassified | Anticoagulant therapy                                                   |
| 2019 | Male | 38  | NN          | PMF, stage I        | 234          | 133    | 0.433 (43.3) | Splenic infarction          | Hydrea                                                                   |
| 2017 | Male | 54  | MN          | PMF, stage II       | 507          | 135    | 0.514 (51.4) | Mesenteric venous thrombosis | Hydrea, anticoagulant therapy                                             |
| 2018 | Female | 76 | MM         | PMF, stage III      | 145          | 136    | 0.41 (41)   | -               | Hydrea, anticoagulant therapy                                             |
| 2019 | Male | 65  | NN          | PMF, stage III      | 248          | 137    | 0.427 (42.7) | -               | Observation                                                               |
| 2017 | Female | 65 | MM         | PMF, stage II       | 1052         | 141    | 0.414 (41.4) | -               | Hydrea, anticoagulant therapy                                             |
| 2016 | Male | 59  | MN          | PMF, stage II       | 674          | 145    | 0.424 (42.4) | -               | Anticoagulant therapy, targeted therapy by JAKAVI                         |
Bleeding and thrombotic events are accepted as common complications of myelofibrosis and contribute significantly to the morbidity and mortality of the condition. A few studies only have evaluated the frequency of these events, their characteristics, and their prognostic impact. According to Devendra et al.,[11] thrombotic events in MF are about as common as in essential thrombocythemia but less common than in polycythemia vera, while bleeding events are relatively more common in MF than in ET or PV. In a study of 155 patients, 11.6% had thrombotic events during a median follow-up of 4.2 years.[7] In a study of 707 patients with PMF, thromboses were diagnosed in 7.2% patients. A subsequently larger number of patients (35%) in our study showed positive history of thrombotic/vascular events, independently from the sex and the JAK2 mutational status.

The pathogenesis of vascular events in MF requires further investigation. Some authors state that age >60 and pre-fibrotic PMF are consistently associated with higher risk of thrombosis while thrombocytosis and JAK2 positivity are not associated with risk of bleeding.[11] The link between MF with other hereditary or acquired thrombophilic states is virtually unknown. The pro-thrombotic role of JAK2 V617F mutation in PV or ET is well established and is included in the thrombotic risk model for ET[12], but remains to be clarified in patients with MF. More recently, JAK2 V617F mutation has been found to carry an increased risk of thrombotic complications.[13] The majority of patients in our study with MF have one or both alleles mutated for JAK2 V617F mutation (23/37 or 62%). 69% of patients with JAK2 mutation have previous thrombotic event, while 58% of JAK2 negative patients are non-thrombotic. Even if there is an observed difference between the groups, a statistical significance has not been found. Those results need to be further confirmed by including more patients and increasing the statistical power of the analysis.

The role of JAK2 V617F mutation in thrombosis in patients with MPN has been recognized. A mutated JAK2

Table 2. Mean values of thrombocytes, hemoglobin, and hematocrit in patients with or without thrombotic events

| Year | Sex | Age | JAK2 status | Diagnosis and stage | Thr $(\times 10^9/L)$ | Hg (g/L) | Hct (%) | Thrombotic event | Management |
|------|-----|-----|-------------|---------------------|----------------------|---------|---------|-----------------|-----------|
| 2017 | Male | 59  | MN          | PMF, stage I        | 292                  | 148     | 0.384 (38.4) | Microthromboses | Hydrea, anticoagulant therapy |
| 2018 | Female | 56  | MN          | PMF, stage II       | 811                  | 148     | 0.462 (46.2) | Thromboangiitis obliterans | Hydrea |
| 2019 | Male | 69  | MM          | PMF, stage II, post-PV | 524                  | 152     | 0.557 (55.7) | Brain infarction | Targeted therapy by JAKAVI |
| 2018 | Male | 71  | MN          | PMF, stage II       | 173                  | 156     | 0.557 (55.7) | - | Hydrea |
| 2016 | Male | 57  | NN          | PMF, stage I, II PV | 169                  | 197     | 0.515 (51.5) | - | Bloodletting, anticoagulant therapy |

Hct: hematocrit; Hg: hemoglobin; Thr: thrombocytes; PMF: primary myelofibrosis; post-EV: post erythremia vera; post-ET: post essential thrombocythemia; NN: individuals homozygous for the wild type JAK2 (lack of mutation); MN: individuals heterozygous for the JAK2 V617F mutation (mutation in one allele); MM: individuals homozygous for the JAK2 V617F mutation (mutation in both alleles)
may not only increase the platelet number but also alter the platelet function, thereby playing a role in thrombogenesis. JAK2 V617F mutation has been reported to cause changes in the process of platelet formation from megakaryocytes in a knock-in mouse model of ET.[14] The platelets were found to be prothrombotic and demonstrated enhanced reactivity to different agonists.[14] The levels of thrombocytes, Hg and Ht are slightly higher in patients with thrombotic incidents compared to non-thrombotic patients. However, we have found no statistical significance among the groups.

The pathogenesis of thrombosis in MPN patients is complex. Disease related factors, such as an increase in blood cell counts (i.e., leukocytosis, erythrocytosis, and thrombocytosis), and more importantly, presence of JAK2 mutation, can interact with non-disease patient related factors such as age, previous history of thrombotic events, obesity, hyper-tension, hyperlipidemia, and presence of thrombophilic defects.[15] In our study, we did not find statistical significance also between the levels of Hg and Ht and the presence of JAK2 V617F mutation in homozygous or heterozygous states (p=0.173 and p=0.695, respectively); however, it was correlated with the Thr level (p=0.098). The idea that patients with MPN-related cerebral venous thrombosis (CVT) should be treated with long-term anticoagulation with VKAs (vit. K antagonists) is presented by some authors.[15] Based on our results, we think that patients with MF, irrespectively of their JAK2 mutational status, are more prone to develop thrombotic complications and have to be treated with caution, including some anticoagulants in the regular therapeutic regimes.

CONCLUSIONS

Patients with myelofibrosis are prone to developing thrombotic complications independently of their JAK2 mutational status. Even in a cohort of small size (myelofibrosis is a rare event with an incidence of approximately 1.5:100,000 in USA) (https://rarediseases.org/rare-diseases/primary-myelofibrosis), the frequency of a thrombotic incidence is not significantly related to JAK2 V617F mutation. Rendering an account to the possible life-threatening complications of such events, treatment decisions should be undertaken upon possible antithrombotic prevention in MF. The thrombotic risk assessment should be based on a combination of clinical risk factors (patient, disease-related, and treatment-related) and a panel of biological markers extending beyond the full blood count.

Author contributions

D.N. wrote the manuscript, A.R. revised it and supplied patients’ data

Conflict of Interest

The author reports no conflicts of interest. The authors are responsible for the content and writing of the paper.

Financial support

The authors received no financial support.

REFERENCES

1. O’Sullivan JM, Harrison CN. Myelofibrosis: clinicopathologic features, prognosis, and management. Clin Adv Hematol Oncol 2018; 16(2):121–31.
2. Nikolova D, Yordanov A, Damyanova V, et al. Janus kinase V617F mutation detection in patients with myelofibrosis. Balkan J Med Genet 2019; 22(1):57–60.
3. Guy A, James C. La thrombose au cours des néoplasies myéloprolifératives. Influence de la mutation JAK2V617F. [Pathogenesis of thrombosis in JAK2V617F myeloproliferative neoplasms]. Med Sci (Paris) 2019; 35(8-9):651–8 [French].
4. Barbui T, Carobbio A, Cervantes F, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010; 115(4):778–82.
5. Nelson ME, Steensma DP. JAK2 V617F in myeloid disorders: what do we know now, and where are we headed? Leuk Lymphoma 2006; 47(2):177–94.
6. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127(20):2391–405.
7. Cervantes F, Alvarez-Larran A, Arellano-Rodrigo E, et al. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. Leukemia 2006; 20(1):55–60.
8. Wehmeier A, Daum I, Jamin H, et al. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol 1991; 63(2):101–6.
9. Rupoli S, Goteri G, Picardi P, et al. Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis. Diagn Pathol 2015; 10:29.
10. Kander EM, Raza S, Zhou Z, et al. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. Int J Hematol 2015; 102(5):587–93.
11. Devendra KC, Falchi L, Verstovsek S. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. Ann Hematol. 2017; 96(10):1595–604.
12. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocytemia (IPSET-thrombosis). Blood 2012; 120(26):5128–33.
13. Martin K. Risk factors for and management of MPN-associated bleeding and thrombosis. Curr Hematol Malig Rep 2017; 12(5):389–96.
14. Hobbs CM, Manning H, Bennett C, et al. JAK2 V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model.
Тромботические инциденты у пациентов с миелофиброзом предполагают, что они не зависят от мутационного статуса JAK2 V617F

Драгомира Николова1,2, Атанас Радинов3

1 Кафедра медицинской генетики, Медицинский университет - София, София, Болгария
2 Лаборатория генетики, УМБАЛ „Св. Иван Рилски“, София, Болгария
3 Клиника гематологии, УМБАЛ „Св. Иван Рилски“, София, Болгария

Адрес для корреспонденции: Драгомира Николова, Кафедра медицинской генетики, Медицинский университет - София, София, Болгария; Email: gdnikolova@gmail.com; Тел.: +359 895 784 096

Дата получения: 27 июля 2021 • Дата приемки: 8 октября 2021 • Дата публикации: 31 августа 2022

Образец цитирования: Nikolova D, Radinov A. Thrombotic incidents in patients with myelofibrosis suggest to be independent of JAK2 V617F mutational status. Folia Med (Plovdiv) 2022;64(4):655-660. doi: 10.3897/folmed.64.e72175.

Резюме

Введение: Миелофиброз (МФ) относится к группе состояний, известных как филадельфийско-негативные миелопролиферативные новообразования (МПН). Кровотечения или различные сосудистые осложнения могут быть основными причинами заболеваемости и смертности больных МФ. Тромбоз, связанный с МПН, представляет собой многофакторный процесс, и в случае миелофиброза мало что известно. Факторы риска тромботических осложнений при МФ оценивались редко.

Цель: Целью этого исследования было изучение частоты тромботических событий при МФ и роли мутации JAK2 V617F как фактора риска тромботических событий у пациентов с МФ.

Материалы и методы: В нашем исследовании было обследовано 37 пациентов у 35% которых в прошлом были тромботические явления. Все пациенты были госпитализированы в гематологическую клинику Университетской больницы „Свети Иван Рилски“, София, Болгария, в период с 2016 по 2019 год, и им был поставлен диагноз на основании критериев ВОЗ 2016 года.

Результаты: У большинства пациентов (23, 62%) обнаружена мутация JAK2 (янус-киназа) V617F, несущая один (16, 70%) или два (7, 30%) мутантных аллеля. У тринадцати пациентов (35%) в прошлом были тромботические явления, а 9 из них (69%) являются носителями мутации JAK2 V617F. Четырнадцать пациентов без тромботического анамнеза (24, 58%) также были носителями мутации JAK2 V617F.

Заключение: В целом мы не обнаружили статистически значимой разницы между мутацией JAK2 V617F и частотой тромботических событий. С учетом возможных жизнеугрожающих осложнений решение о лечении следует принимать на фоне возможной антитромботической профилактики при МФ.

Ключевые слова

мутация JAK2, миелофиброз (МФ), тромботические явления, фактор риска